Alimera acquires u.s. commercial rights to yutiq®

Atlanta, may 18, 2023 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced its acquisition of additional commercialization rights for yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from eyepoint pharmaceuticals, inc. (eyepoint). a live conference call will be hosted today at 8:30 a.m. et to provide a corporate update. please refer to the information in the paragraphs below for conference call dial-in information and webcast registration.
ALIM Ratings Summary
ALIM Quant Ranking